750 related articles for article (PubMed ID: 7966789)
1. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
2. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
3. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1992 Aug; 148(2 Pt 1):302-6; discussion 306-7. PubMed ID: 1635123
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Lehmann J; Retz M; Wiemers C; Beck J; Thüroff J; Weining C; Albers P; Frohneberg D; Becker T; Funke PJ; Walz P; Langbein S; Reiher F; Schiller M; Miller K; Roth S; Kälble T; Sternberg D; Wellek S; Stöckle M;
J Clin Oncol; 2005 Aug; 23(22):4963-74. PubMed ID: 15939920
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
6. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
8. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
10. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement.
Stöckle M; Wellek S; Meyenburg W; Voges GE; Fischer U; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Urology; 1996 Dec; 48(6):868-75. PubMed ID: 8973669
[TBL] [Abstract][Full Text] [Related]
11. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
13. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
15. [Postoperative adjuvant M-VAC chemotherapy for invasive bladder cancer].
Yamashita S; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Yushita Y; Sakuragi T
Hinyokika Kiyo; 1992 May; 38(5):519-24. PubMed ID: 1609658
[TBL] [Abstract][Full Text] [Related]
16. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
Inoue K; Slaton JW; Karashima T; Yoshikawa C; Shuin T; Sweeney P; Millikan R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4866-73. PubMed ID: 11156246
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
Voce S; Montanari F; Arnone S; Dal Pozzo C; Suprani G; Cerullo G; Fornarola V
Arch Esp Urol; 1992 Jun; 45(5):491-8. PubMed ID: 1510485
[TBL] [Abstract][Full Text] [Related]
20. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
Klän R; Knispel H; Huland H
Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]